1	An	An	B-NP	DT	O	2	NMOD	-1
2	antibody	antibody	I-NP	NN	O	8	SUB	-1
3	directed	direct	B-VP	VBN	O	2	NMOD	-1
4	against	against	B-PP	IN	O	3	VMOD	0
5	PDGF	PDGF	B-NP	NN	B-protein	7	NMOD	-1
6	receptor	receptor	I-NP	NN	I-protein	7	NMOD	-1
7	beta	beta	I-NP	NN	I-protein	4	PMOD	-1
8	enhances	enhance	B-VP	VBZ	O	0	ROOT	17	enhances
9	the	the	B-NP	DT	O	10	NMOD	-1
10	antitumor	antitumor	I-NP	NN	O	14	NMOD	-1
11	and	and	O	CC	O	14	NMOD	-1
12	the	the	B-NP	DT	O	14	NMOD	-1
13	anti-angiogenic	anti-angiogenic	I-NP	JJ	O	14	NMOD	3	angiogenic
14	activities	activity	I-NP	NNS	O	8	OBJ	18	activities
15	of	of	B-PP	IN	O	14	NMOD	-1
16	an	an	B-NP	DT	O	20	NMOD	-1
17	anti-VEGF	anti-VEGF	I-NP	JJ	B-protein	20	NMOD	-1
18	receptor	receptor	I-NP	NN	I-protein	20	NMOD	-1
19	2	2	I-NP	CD	I-protein	20	NMOD	-1
20	antibody	antibody	I-NP	NN	I-protein	15	PMOD	-1
21	.	.	O	.	O	8	P	-1

1	Platelet-derived	Platelet-derived	B-NP	JJ	B-protein	3	NMOD	-1
2	growth	growth	I-NP	NN	I-protein	3	NMOD	0
3	factor	factor	I-NP	NN	I-protein	9	NMOD	-1
4	(	(	O	(	O	6	DEP	-1
5	PDGF	PDGF	B-NP	NN	B-protein	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	and	and	O	CC	O	9	NMOD	-1
8	its	its	B-NP	PRP$	O	9	NMOD	-1
9	receptors	receptor	I-NP	NNS	O	13	SUB	-1
10	(	(	O	(	O	12	DEP	-1
11	PDGFR	PDGFR	B-NP	NN	B-protein	12	DEP	-1
12	)	)	O	)	O	9	NMOD	-1
13	play	play	B-VP	VBP	O	0	ROOT	0
14	important	important	B-NP	JJ	O	15	NMOD	0
15	roles	role	I-NP	NNS	O	13	OBJ	0
16	in	in	B-PP	IN	O	13	VMOD	-1
17	tumorigenesis	tumorigenesis	B-NP	NN	O	16	PMOD	-1
18	through	through	B-PP	IN	O	13	VMOD	0
19	stimulating	stimulate	B-VP	VBG	O	18	PMOD	17	stimulating
20	tumor	tumor	B-NP	NN	O	21	NMOD	-1
21	growth	growth	I-NP	NN	O	19	OBJ	4	growth
22	and	and	O	CC	O	19	VMOD	-1
23	promoting	promote	B-VP	VBG	O	19	VMOD	17	promoting
24	angiogenesis	angiogenesis	B-NP	NN	O	23	OBJ	3	angiogenesis
25	via	via	B-PP	IN	O	23	VMOD	0
26	enhancing	enhance	B-VP	VBG	O	25	PMOD	17	enhancing
27	pericyte	pericyte	B-NP	NN	O	28	NMOD	-1
28	recruitment	recruitment	I-NP	NN	O	31	NMOD	14	recruitment
29	and	and	O	CC	O	31	NMOD	-1
30	vessel	vessel	B-NP	NN	O	31	NMOD	-1
31	maturation	maturation	I-NP	NN	O	26	OBJ	2	maturation
32	.	.	O	.	O	13	P	-1

1	Here	Here	B-ADVP	RB	O	3	VMOD	-1
2	we	we	B-NP	PRP	O	3	SUB	-1
3	produced	produce	B-VP	VBD	O	0	ROOT	0
4	a	a	B-NP	DT	O	6	NMOD	-1
5	neutralizing	neutralize	I-NP	VBG	O	6	NMOD	-1
6	antibody	antibody	I-NP	NN	O	8	NMOD	-1
7	,	,	O	,	O	8	P	-1
8	1B3	1B3	B-NP	NN	B-protein	3	OBJ	-1
9	,	,	O	,	O	8	P	-1
10	directed	direct	B-VP	VBN	O	8	NMOD	-1
11	against	against	B-PP	IN	O	10	VMOD	0
12	mouse	mouse	B-NP	NN	B-protein	13	NMOD	-1
13	PDGFRbeta	PDGFRbeta	I-NP	NN	I-protein	11	PMOD	-1
14	.	.	O	.	O	3	P	-1

1	1B3	1B3	B-NP	NN	B-protein	2	SUB	-1
2	binds	bind	B-VP	VBZ	O	0	ROOT	15	binds
3	to	to	B-PP	TO	O	2	VMOD	-1
4	PDGFRbeta	PDGFRbeta	B-NP	NN	B-protein	3	PMOD	-1
5	with	with	B-PP	IN	O	2	VMOD	-1
6	high	high	B-NP	JJ	O	7	NMOD	-1
7	affinity	affinity	I-NP	NN	O	5	PMOD	0
8	(	(	O	(	O	12	DEP	-1
9	9x10	9x10	B-NP	CD	O	12	DEP	-1
10	(	(	O	(	O	12	DEP	-1
11	-11	-11	B-NP	CD	O	12	DEP	-1
12	)	)	O	)	O	7	NMOD	-1
13	M	M	B-NP	NN	O	5	PMOD	-1
14	)	)	O	)	O	13	NMOD	-1
15	and	and	O	CC	O	2	VMOD	-1
16	blocks	block	B-VP	VBZ	O	2	VMOD	18	blocks
17	PDGF-BB	PDGF-BB	B-NP	NN	B-protein	16	OBJ	-1
18	from	from	B-PP	IN	O	16	VMOD	-1
19	binding	bind	B-VP	VBG	O	18	PMOD	15	binding
20	to	to	B-PP	TO	O	19	VMOD	-1
21	the	the	B-NP	DT	O	22	NMOD	-1
22	receptor	receptor	I-NP	NN	O	20	PMOD	-1
23	with	with	B-PP	IN	O	22	NMOD	-1
24	an	an	B-NP	DT	O	25	NMOD	-1
25	IC	IC	I-NP	NN	O	23	PMOD	-1
26	(	(	O	(	O	28	DEP	-1
27	50	50	B-NP	CD	O	28	DEP	-1
28	)	)	O	)	O	25	NMOD	-1
29	of	of	B-PP	IN	O	25	NMOD	-1
30	approximately	approximately	B-NP	RB	O	32	NMOD	-1
31	1.2	1.2	I-NP	CD	O	30	AMOD	-1
32	nM	nM	I-NP	NN	O	29	PMOD	-1
33	.	.	O	.	O	2	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	antibody	antibody	I-NP	NN	O	4	SUB	-1
3	also	also	B-ADVP	RB	O	4	VMOD	-1
4	blocks	block	B-VP	VBZ	O	0	ROOT	18	blocks
5	ligand-stimulated	ligand-stimulated	B-NP	JJ	O	6	NMOD	-1
6	activation	activation	I-NP	NN	O	4	OBJ	17	activation
7	of	of	B-PP	IN	O	6	NMOD	-1
8	PDGFRbeta	PDGFRbeta	B-NP	NN	B-protein	12	NMOD	-1
9	and	and	O	CC	O	12	NMOD	-1
10	downstream	downstream	B-NP	JJ	B-protein	12	NMOD	0
11	signaling	signal	I-NP	VBG	I-protein	12	NMOD	0
12	molecules	molecule	I-NP	NNS	I-protein	7	PMOD	-1
13	,	,	O	,	O	12	P	-1
14	including	include	B-PP	VBG	O	12	NMOD	-1
15	Akt	Akt	B-NP	NN	B-protein	18	NMOD	-1
16	and	and	I-NP	CC	O	18	NMOD	-1
17	MAPK	MAPK	I-NP	NN	B-protein	18	NMOD	-1
18	p42/44	p42/44	I-NP	NN	I-protein	14	PMOD	-1
19	,	,	O	,	O	18	P	-1
20	in	in	B-PP	IN	O	18	NMOD	-1
21	tumor	tumor	B-NP	NN	B-cell_type	22	NMOD	-1
22	cells	cell	I-NP	NNS	I-cell_type	20	PMOD	-1
23	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	7	VMOD	-1
2	animal	animal	B-NP	NN	O	3	NMOD	-1
3	studies	study	I-NP	NNS	O	1	PMOD	-1
4	,	,	O	,	O	7	P	-1
5	1B3	1B3	B-NP	NN	B-protein	7	SUB	-1
6	significantly	significantly	B-ADVP	RB	O	7	VMOD	-1
7	enhanced	enhance	B-VP	VBD	O	0	ROOT	17	enhanced
8	the	the	B-NP	DT	O	9	NMOD	-1
9	antitumor	antitumor	I-NP	NN	O	13	NMOD	-1
10	and	and	O	CC	O	13	NMOD	-1
11	the	the	B-NP	DT	O	13	NMOD	-1
12	anti-angiogenic	anti-angiogenic	I-NP	JJ	O	13	NMOD	3	angiogenic
13	activities	activity	I-NP	NNS	O	7	OBJ	18	activities
14	of	of	B-PP	IN	O	13	NMOD	-1
15	DC101	DC101	B-NP	NN	B-protein	18	NMOD	-1
16	,	,	O	,	O	18	P	-1
17	an	an	B-NP	DT	O	18	NMOD	-1
18	antibody	antibody	I-NP	NN	O	14	PMOD	-1
19	directed	direct	B-VP	VBN	O	18	NMOD	-1
20	against	against	B-PP	IN	O	19	VMOD	0
21	mouse	mouse	B-NP	NN	B-protein	26	NMOD	-1
22	vascular	vascular	I-NP	JJ	I-protein	26	NMOD	-1
23	endothelial	endothelial	I-NP	JJ	I-protein	26	NMOD	-1
24	growth	growth	I-NP	NN	I-protein	26	NMOD	0
25	factor	factor	I-NP	NN	I-protein	26	NMOD	-1
26	receptor	receptor	I-NP	NN	I-protein	20	PMOD	-1
27	2	2	B-NP	CD	I-protein	26	NMOD	-1
28	,	,	O	,	O	7	P	-1
29	in	in	B-PP	IN	O	7	VMOD	-1
30	a	a	O	DT	O	45	NMOD	-1
31	pancreatic	pancreatic	O	JJ	O	45	NMOD	-1
32	(	(	O	(	O	34	DEP	-1
33	BxPC-3	BxPC-3	B-NP	NN	B-protein	34	DEP	-1
34	)	)	O	)	O	31	AMOD	-1
35	and	and	O	CC	O	45	NMOD	-1
36	a	a	B-NP	DT	O	45	NMOD	-1
37	non-small	non-small	I-NP	JJ	B-cell_line	45	NMOD	-1
38	cell	cell	I-NP	NN	I-cell_line	45	NMOD	-1
39	lung	lung	I-NP	NN	I-cell_line	45	NMOD	-1
40	(	(	O	(	I-cell_line	45	NMOD	-1
41	NCI-H460	NCI-H460	B-NP	NN	I-cell_line	45	NMOD	-1
42	)	)	O	)	I-cell_line	45	NMOD	-1
43	tumor	tumor	B-NP	NN	I-cell_line	45	NMOD	-1
44	xenograft	xenograft	I-NP	NN	I-cell_line	45	NMOD	-1
45	models	model	I-NP	NNS	I-cell_line	29	PMOD	-1
46	.	.	O	.	O	7	P	-1

1	Treatment	Treatment	B-NP	NN	O	13	SUB	19	Treatment
2	with	with	B-PP	IN	O	1	NMOD	-1
3	the	the	B-NP	DT	O	4	NMOD	-1
4	combination	combination	I-NP	NN	O	2	PMOD	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	1B3	1B3	B-NP	NN	B-protein	8	NMOD	-1
7	and	and	I-NP	CC	O	8	NMOD	-1
8	DC101	DC101	I-NP	NN	O	5	PMOD	-1
9	in	in	B-PP	IN	O	8	NMOD	-1
10	BxPC-3	BxPC-3	B-NP	NN	O	12	NMOD	-1
11	xenograft-bearing	xenograft-bearing	I-NP	NN	O	12	NMOD	-1
12	mice	mouse	I-NP	NNS	O	9	PMOD	-1
13	resulted	result	B-VP	VBD	O	0	ROOT	17	resulted
14	in	in	B-PP	IN	O	13	VMOD	-1
15	tumor	tumor	B-NP	NN	O	16	NMOD	-1
16	regression	regression	I-NP	NN	O	14	PMOD	18	regression
17	in	in	B-PP	IN	O	16	NMOD	-1
18	58	58	B-NP	CD	O	19	NMOD	-1
19	%	%	I-NP	NN	O	17	PMOD	-1
20	of	of	B-PP	IN	O	19	NMOD	-1
21	mice	mouse	B-NP	NNS	O	20	PMOD	-1
22	compared	compare	B-VP	VBN	O	16	NMOD	-1
23	to	to	B-PP	TO	O	22	VMOD	-1
24	that	that	B-NP	DT	O	23	PMOD	-1
25	in	in	B-PP	IN	O	24	NMOD	-1
26	18	18	B-NP	CD	O	27	NMOD	-1
27	%	%	I-NP	NN	O	25	PMOD	-1
28	of	of	B-PP	IN	O	27	NMOD	-1
29	mice	mouse	B-NP	NNS	O	28	PMOD	-1
30	treated	treat	B-VP	VBN	O	29	NMOD	19	treated
31	with	with	B-PP	IN	O	30	VMOD	-1
32	DC101	DC101	B-NP	NN	B-protein	31	PMOD	-1
33	alone	alone	B-ADVP	RB	O	32	NMOD	-1
34	.	.	O	.	O	13	P	-1

1	Taken	Take	B-VP	VBN	O	6	VMOD	-1
2	together	together	B-ADVP	RB	O	1	VMOD	-1
3	,	,	O	,	O	6	P	-1
4	these	these	B-NP	DT	O	5	NMOD	-1
5	results	result	I-NP	NNS	O	6	SUB	0
6	lend	lend	B-VP	VBP	O	0	ROOT	-1
7	great	great	B-NP	JJ	O	8	NMOD	-1
8	support	support	I-NP	NN	O	6	OBJ	0
9	to	to	B-VP	TO	O	10	VMOD	-1
10	use	use	I-VP	VB	O	6	VMOD	0
11	PDGFRbeta	PDGFRbeta	B-NP	NN	O	12	NMOD	-1
12	antagonists	antagonist	I-NP	NNS	O	10	OBJ	-1
13	in	in	B-PP	IN	O	12	NMOD	-1
14	combinations	combination	B-NP	NNS	O	13	PMOD	-1
15	with	with	B-PP	IN	O	14	NMOD	-1
16	other	other	B-NP	JJ	O	20	NMOD	-1
17	antitumor	antitumor	I-NP	JJ	O	19	AMOD	-1
18	and/or	and/or	I-NP	CC	O	19	AMOD	-1
19	anti-angiogenic	anti-angiogenic	I-NP	JJ	O	20	NMOD	3	angiogenic
20	agents	agent	I-NP	NNS	O	15	PMOD	-1
21	in	in	B-PP	IN	O	20	NMOD	-1
22	the	the	B-NP	DT	O	23	NMOD	-1
23	treatment	treatment	I-NP	NN	O	21	PMOD	19	treatment
24	of	of	B-PP	IN	O	23	NMOD	-1
25	a	a	B-NP	DT	O	26	NMOD	-1
26	variety	variety	I-NP	NN	O	24	PMOD	-1
27	of	of	B-PP	IN	O	26	NMOD	-1
28	cancers	cancer	B-NP	NNS	O	27	PMOD	-1
29	.	.	O	.	O	6	P	-1

